Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Inclusion Criteria: Histologically confirmed relapsed or refractory solid tumor or lymphoma including: Neuroblastoma Osteosarcoma Ewing's sarcoma Rhabdomyosarcoma Wilms tumor CNS tumors Histological verification not required for brainstem tumors No acute leukemia Not eligible for higher priority COG phase I/II study Performance status - Karnofsky 50-100% (over age 10) Performance status - Lansky 50-100% (age 10 and under) At least 2 months Absolute neutrophil count at least 1,000/mm^3 Platelet count at least 75,000/mm^3 (transfusion independent) Hemoglobin at least 8.0 g/dL (transfusion allowed) No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement Bilirubin no greater than 1.5 times normal SGPT no greater than 5 times normal Albumin at least 2 g/dL Creatinine no greater than 1.5 times normal Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal Shortening fraction at least 27% by echocardiogram Ejection fraction at least 50% by MUGA Stable neurologic deficits within the past 2 weeks for patients with CNS tumors CNS toxicity less than grade 2 No active graft-versus-host disease No active uncontrolled infection or other serious medical condition No uncontrolled diabetes mellitus Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception At least 7 days since prior biologic therapy and recovered Prior bone marrow or stem cell transplantation allowed At least 6 months since prior allogeneic stem cell transplantation At least 1 week since prior growth factors No concurrent immunomodulating agents At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered No other concurrent chemotherapy Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks prior to study Concurrent corticosteroids allowed only for increased intracranial pressure in patients with CNS tumors At least 2 weeks since prior local (small port) palliative radiotherapy At least 6 months since prior radiotherapy to 50% or more of the pelvis At least 6 months since prior craniospinal radiotherapy At least 6 weeks since other prior substantial bone marrow radiotherapy Recovered from prior radiotherapy No concurrent radiotherapy except localized palliative radiotherapy No concurrent anticonvulsants